Last updated by Peer reviewed by Dr Colin Tidy
Last updated Meets Patient’s editorial guidelines

Added to Saved items
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

A paraprotein is a monoclonal immunoglobulin or light chain present in the blood or urine; it is produced by a clonal population of mature B cells, most commonly plasma cells.[1]

Paraproteinaemia represents a group of related diseases characterised by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. Plasma cell disorders can be considered as a spectrum of conditions ranging from monoclonal gammopathy of undetermined significance (MGUS), through asymptomatic, to symptomatic myeloma.[1]

The incidence of a paraprotein is 3.2% in people aged over 50 years.[1]

  • Artefacts: heparinised blood sample.
  • MGUS:[2, 3]
    • MGUS is defined by a low level of paraprotein <30 g/L, bone marrow plasma cells <10% and the absence of myeloma-related organ or tissue damage (predominantly renal, skeletal or bone marrow impairment).
    • Patients are often elderly and in good health.
    • MGUS requires no therapy and the overall risk of progression to myeloma is 1% per year.[1]
    • Follow-up must be continued indefinitely because multiple myeloma, amyloidosis, macroglobulinaemia or related disorders may occur.
  • Non-Hodgkin's lymphoma.

Malignant neoplastic conditions:

  • Multiple myeloma. Effective treatments for myeloma have been developed over the last 15 years. Myeloma remains incurable but there have been improvements in overall survival and quality of life. Treatments include bortezomib, thalidomide and stem cell transplantation.[4]
  • Lymphoproliferative diseases including chronic lymphocytic leukaemia, non-Hodgkin's lymphoma and Waldenstrom's macroglobulinaemia.
  • Plasmacytoma (a tumour consisting of abnormal plasma cells that grows within the soft tissue or skeleton).
  • Heavy chain diseases: there are 3 variants - gamma, alpha and mu heavy chain disease.[5] The alpha variant is most common, occurring particularly in people from the Mediterranean and Middle East and often presenting with weakness, fatigue and fever.
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes).
  • Amyloidosis.
  • Non-malignant systemic disease:[1]
    • Autoimmune disease: rheumatoid arthritis, scleroderma, Hashimoto's thyroiditis. .
    • Cutaneous disease: pyoderma gangrenosum, necrobiotic xanthogranulomatosis.
    • Liver disease: hepatitis, cirrhosis.
    • Infectious disease: tuberculosis, bacterial endocarditis.
  • Miscellaneous syndromes:
    • Schnitzler's syndrome (chronic, non-pruritic urticaria associated with recurrent fever, bone pain, arthralgia or arthritis, and a monoclonal IgM gammopathy).
  • Paraproteinaemia may be asymptomatic and discovered incidentally.
  • Often nonspecific presentation with fever, malaise, and bone pain.
  • Clinical indications for screening for M-protein:[1, 6]
    • Malaise and fatigue.
    • Bone disease (persistent back pain, osteopenia or lytic lesions).
    • Impaired renal function.
    • Normochromic normocytic anaemia ± pancytopenia.
    • Hypercalcaemia (confusion, muscle weakness, constipation, thirst, polyuria).
    • Recurrent bacterial infections.
    • Hyperviscosity (headache, visual disturbance, cognitive impairment, mucosal bleeding, breathlessness).
    • Nephrotic syndrome, cardiac failure, malabsorption.
    • Peripheral neuropathies, carpal tunnel syndrome.
    • Incidental persistent elevated erythrocyte sedimentation rate (ESR) or plasma viscosity (PV) or serum protein or globulin.

The differentiation of benign paraproteinaemia from neoplastic states is based on the absence of bone marrow disease, a relatively low and constant concentration of serum paraprotein, the absence of urine light chain excretion and normal levels of other serum immunoglobulins. It is important to test both urine and blood for paraprotein. In 15% of myeloma cases the diagnosis would be missed if only serum electrophoresis was performed with testing urine for Bence Jones' proteins.

  • Serum protein electrophoresis showing M-protein: total protein and protein electrophoresis with paraprotein quantification, paraprotein typing, immunoglobulins G, A, M; beta-2-microglobulin.[7]
  • FBC, blood film, ESR: underlying cause - eg, hypercalcaemia, high total protein, and high ESR or PV in patients with myeloma.
  • Urine protein: Bence Jones' proteins (usually indicate multiple myeloma, amyloidosis or Waldenström's macroglobulinaemia).
  • Bone marrow aspiration and trephine biopsy.

Management will depend on the underlying cause.

This will depend on the underlying cause. In 2020 the five-year year survival rate for multiple myeloma was 52%.[6] Patients with MGUS have a 1% annual risk of progression to myeloma.[8]

Are you protected against flu?

See if you are eligible for a free NHS flu jab today.

Check now

Further reading and references

  1. Cook L, Macdonald DH; Management of paraproteinaemia. Postgrad Med J. 2007 Apr83(978):217-23.

  2. Myeloma and MGUS A Guide for GPs; Myeloma UK

  3. Merlini G, Palladini G; Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program. 20122012:595-603. doi: 10.1182/asheducation-2012.1.595.

  4. Myeloma: diagnosis and management; NICE Guidance, (February 2016 - last updated October 2018)

  5. Bianchi G, Anderson KC, Harris NL, et al; The heavy chain diseases: clinical and pathologic features. Oncology (Williston Park). 2014 Jan28(1):45-53.

  6. Multiple myeloma; NICE CKS, April 2022 (UK access only)

  7. Roberts-Thomson PJ, Nikoloutsopoulos T, Smith AJ; IgM paraproteinaemia: disease associations and laboratory features. Pathology. 2002 Aug34(4):356-61.

  8. MGUS Prognosis; QxMD